



Fundación MEDINA

Discovering the Future

September 16, 2013-

Fundacion MEDINA is committed to the discovery of new drugs to treat tropical diseases: Malaria, Trypanosomiasis, Leishmaniasis and Coccidiosis:

Fundacion MEDINA (Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía), is a research organization focused on the discovery of novel drugs and bioactive molecules from natural products to address unmet medical needs in infectious, rare and neglected tropical diseases such as malaria, among other projects.

In this regard, PARAMET is a Marie Curie Initial Training Network (ITN) funded by the European Commission and currently involves 12 scientific and industrial partners from 6 European countries. The project is coordinated by Professor Sylke Müller at the University of Glasgow, UK. The project started on June 1, 2012 and will be funded, by the European Commission for 48 months, until May 31, 2016 (<http://www.paramet.eu/>).

PARAMET will train a new generation of European scientists in the requisites of preclinical drug discovery, combining academic excellence in innovation with industrial rigor and thus providing inter-disciplinary training from an academic and industrial perspective.

Parasites have a devastating toll on health and economic productivity, infecting Man and also domestic livestock. Advances in genomics, transcriptomics, metabolomics and protein chemistry, alongside computational systems biology are integral to the activities of the network and will be used to obtain new insights into the metabolic peculiarities found in parasites that are exploitable for drug discovery against diseases such as malaria, trypanosomiasis, leishmaniasis and the coccidiosis

Fundacion MEDINA's role is to open the doors of its center to one of the researchers for training in multiple disciplines developed at the Fundacion, allowing this young scientist to develop his doctoral thesis. Through this project, the collection of natural products from the Fundacion will be screened to test biological activity against various parasitic diseases. MEDINA will determine the molecules responsible for this activity and will select the best candidates to undergo drug safety testing to determine that the future drugs will not pose a risk to human health. This research will be done in collaboration with different groups from the Institute of Parasitology and Biomedicine Lopez-Neyra of National Research Council of Granada.



Fundación MEDINA

Discovering the Future

The Fundación is part of the Network of Tropical Diseases ISCIII (RICET), within the group of chemotherapy for parasitic diseases (<http://www.ricet.es/es/>).

About Fundación MEDINA

Fundación MEDINA is a non-profit research organization established in Granada, Spain, from the private-public partnership between the Government of Andalucía, the University of Granada and Merck Sharp and Dohme de España S.A. Fundación MEDINA owns one of the largest and most chemically diverse microbial Natural Products Libraries of extracts with a long, successful track record in delivering novel drug candidates in the pharmaceutical sector. Fundación MEDINA has unique expertise in natural products microbiology, chemistry and high throughput screening, and develops drug discovery programs in infectious diseases (including tuberculosis and parasitic diseases), oncology, and rare diseases. Fundación MEDINA is establishing contract research collaborations and partnerships with pharma and biotech companies to discover novel therapeutics.

Contact:

Olga Genilloud, PhD

Fundación MEDINA

Avda del Conocimiento 3

Parque Tecnológico Ciencias de la Salud

18100 Armilla, Granada, SPAIN

Phone +34 958 993 965

Fax +34 958 846 710

olga.genilloud@medinaandalucia.es